Hypertrophic Cardiomyopathy
Epidemiology and Natural History:
1.
Autosomal
dominant with heterogeneity and incomplete penetrance.
2.
Family
history known in 50%.
3.
Some
can run a benign course, but there is need to identify risk for adverse events.
4.
Sudden
cardiac death as high as 4-6% per year in children and adolescents, 1-2% per
year in adults.
5.
Death
occurs as result of
·
Sudden
cardiac death in 51%. Usually young
adults. ECG and ECHO cannot help
stratify risk for this.
·
Heart
failure in 36%.
·
Stroke
in 13%. This is a result of atrial
fibrillation
1.
Dyspnoea
2.
Chest
pain
3.
Arrhythmias
(palpitation)
4.
Syncope
5.
Sudden
death
6.
Systolic
murmur changing with position
1.
Chest
X-ray is normal – the heart is hypertrophied (septum), but not dilated.
2.
ECG
normal in only 7% of all patients and 27% of asymptomatic patients. Abnormalities almost always increased LV
voltage with tall QRS and ST depression.
Usually precordial T wave inversion.
50% have a narrow Q in 1, AVL, V5, V6.
Some will have Q waves in inferior leads (2, 3, AVF)
3.
ECHO
usually shows the septal hypertrophy with obstruction of LV outflow.
1.
Medical
treatment includes beta blockers or verapamil to attenuate the outflow
gradient. Amiodarone is used in
presence of supraventricular or ventricular arrhythmias.
2.
While
medical treatment may help symptoms, it has no effect on progression of the
disease or on incidence of sudden cardiac death.
3.
Surgical
myomectomy occasionally used.
4.
Inplantable
defibrillators used in presence of known or recurring life-threatening
ventricular arrhythmias.
1.
Unrecognized
killers on ECG. Audio Digest Emergency
Medicine 2007. 24(1)
2.
UpToDate
Ver. 14.2 2006. Natural history of hypertrophic
cardiomyopathy.
3.
UpToDate
Ver. 14.2 2006. Clinical manifestations of hypertrophic
cardiomyopathy.